JIN MEDICAL INTERNATIONAL LTD. (ZJYL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 30, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Feb 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZJYL SEC filings page.
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported $20.7M in revenue for fiscal year 2025, down 12.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
FY2025 shows margin compression and investment-led cash strain after sales contracted and liabilities grew faster than assets.
Operating cash flow moved from-$1.2M in FY2024 to$2.9M in FY2025, so reported profit regained cash backing. But the$6.6M capital outlay exceeded operating cash flow, leaving free cash flow at-$3.7M ; cash generation returned, but did not fund the year's investment.
Revenue contracted while cost of revenue rose
From FY2023 to FY2025, assets grew
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of JIN MEDICAL INTERNATIONAL LTD.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
JIN MEDICAL INTERNATIONAL LTD. has an operating margin of 2.9%, meaning the company retains $3 of operating profit per $100 of revenue. This results in a moderate score of 59/100, indicating healthy but not exceptional operating efficiency. This is down from 15.5% the prior year.
JIN MEDICAL INTERNATIONAL LTD.'s revenue declined 12.0% year-over-year, from $23.5M to $20.7M. This contraction results in a growth score of 38/100.
JIN MEDICAL INTERNATIONAL LTD.'s current ratio of 1.86 indicates adequate short-term liquidity, earning a score of 55/100. The company can meet its near-term obligations, though with limited headroom.
While JIN MEDICAL INTERNATIONAL LTD. generated $2.9M in operating cash flow, capex of $6.6M consumed most of it, leaving -$3.7M in free cash flow. This results in a low score of 14/100, reflecting heavy capital investment rather than weak cash generation.
JIN MEDICAL INTERNATIONAL LTD.'s ROE of 4.0% shows moderate profitability relative to equity, earning a score of 56/100. This is down from 12.8% the prior year.
JIN MEDICAL INTERNATIONAL LTD. scores 5.80, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $173.1M against total liabilities of $23.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
JIN MEDICAL INTERNATIONAL LTD. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, JIN MEDICAL INTERNATIONAL LTD. generates $2.44 in operating cash flow ($2.9M OCF vs $1.2M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
JIN MEDICAL INTERNATIONAL LTD. generated $20.7M in revenue in fiscal year 2025. This represents a decrease of 12.0% from the prior year.
JIN MEDICAL INTERNATIONAL LTD.'s EBITDA was $852K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 78.0% from the prior year.
JIN MEDICAL INTERNATIONAL LTD. reported $1.2M in net income in fiscal year 2025. This represents a decrease of 67.6% from the prior year.
JIN MEDICAL INTERNATIONAL LTD. earned $0.01 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
JIN MEDICAL INTERNATIONAL LTD. recorded an outflow of $3.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
JIN MEDICAL INTERNATIONAL LTD. held $7.5M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
JIN MEDICAL INTERNATIONAL LTD.'s gross margin was 29.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 11.2 percentage points from the prior year.
JIN MEDICAL INTERNATIONAL LTD.'s operating margin was 2.9% in fiscal year 2025, reflecting core business profitability. This is down 12.5 percentage points from the prior year.
JIN MEDICAL INTERNATIONAL LTD.'s net profit margin was 5.8% in fiscal year 2025, showing the share of revenue converted to profit. This is down 9.9 percentage points from the prior year.
JIN MEDICAL INTERNATIONAL LTD.'s ROE was 4.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 8.7 percentage points from the prior year.
Capital Allocation
JIN MEDICAL INTERNATIONAL LTD. invested $1.6M in research and development in fiscal year 2025. This represents an increase of 4.0% from the prior year.
JIN MEDICAL INTERNATIONAL LTD. invested $6.6M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 4473.9% from the prior year.
Not reported for fiscal year 2025.
ZJYL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Revenue | $20.7M-12.0% | $23.5M+18.6% | $19.8M+3.3% | $19.2M-7.6% | $20.8M |
| Cost of Revenue | $14.4M+4.0% | $13.9M+8.1% | $12.9M+0.2% | $12.8M-10.9% | $14.4M |
| Gross Profit | $6.0M-36.4% | $9.5M+40.1% | $6.8M+9.5% | $6.2M-2.6% | $6.4M |
| R&D Expenses | $1.6M+4.0% | $1.5M-3.0% | $1.5M-18.5% | $1.9M+20.8% | $1.6M |
| SG&A Expenses | $3.9M-11.2% | $4.4M+83.9% | $2.4M+9.2% | $2.2M+0.6% | $2.2M |
| Operating Income | $608K-83.3% | $3.6M+26.9% | $2.9M+34.6% | $2.1M-19.0% | $2.6M |
| EBITDA | $852K-78.0% | $3.9M+25.3% | $3.1M+24.1% | $2.5M-16.3% | $3.0M |
| Income Tax | $215K-71.9% | $764K+122.2% | $344K+851.8% | $36K-85.5% | $249K |
| Net Income | $1.2M-67.6% | $3.7M+27.7% | $2.9M+6.3% | $2.7M+2.8% | $2.6M |
| EPS (Basic) | $0.01 | $0.020.0% | $0.020.0% | $0.020.0% | $0.02 |
| EPS (Diluted) | $0.01 | $0.020.0% | $0.020.0% | $0.020.0% | $0.02 |
| Diluted Shares (Avg) | 157M | 156M+7.8% | 145M+7.5% | 135M0.0% | 135M |
Not reported in any period shown, so not listed: Interest Expense.
ZJYL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Total Assets | $53.4M+16.5% | $45.8M+39.2% | $32.9M+57.1% | $20.9M | N/A |
| Current Assets | $44.1M+3.1% | $42.8M+37.6% | $31.1M+64.6% | $18.9M | N/A |
| Cash & Equivalents | $7.5M-8.3% | $8.1M+17.4% | $6.9M+44.6% | $4.8M+30.5% | $3.7M |
| Short-Term Investments | $22.2M+19.1% | $18.6M+90.6% | $9.8M+329.2% | $2.3Mn/m | $0 |
| Inventory | $4.9M-4.8% | $5.2M+2.4% | $5.1M-24.9% | $6.7M | N/A |
| Accounts Receivable | $5.8M-1.8% | $5.9M+80.1% | $3.3M-14.3% | $3.8M | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Total Liabilities | $23.8M+38.0% | $17.2M+93.3% | $8.9M+56.5% | $5.7M | N/A |
| Current Liabilities | $23.8M+38.7% | $17.2M+92.2% | $8.9M+56.5% | $5.7M | N/A |
| Non-Current Liabilities | $0-100.0% | $96Kn/m | $0n/m | $0 | N/A |
| Total Equity | $29.6M+2.9% | $28.8M+20.2% | $24.0M+57.4% | $15.2M+8.6% | $14.0M |
| Retained Earnings | $20.9M+4.6% | $20.0M+18.3% | $16.9M+17.5% | $14.4M | N/A |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
ZJYL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Operating Cash Flow | $2.9Mn/m | -$1.2M-138.9% | $3.1M+96.5% | $1.6M-72.9% | $5.8M |
| Depreciation & Amortization | $243K+2.3% | $238K+5.3% | $226K-37.7% | $363K+4.6% | $347K |
| Capital Expenditures | $6.6M+4473.9% | $145K+27.2% | $114K+183.7% | $40K-6.3% | $43K |
| Free Cash Flow | -$3.7Mn/m | -$1.4M-145.2% | $3.0M+94.3% | $1.5M-73.4% | $5.8M |
| Investing Cash Flow | -$10.8Mn/m | -$9.5Mn/m | -$7.7Mn/m | -$121Kn/m | -$1.1M |
| Financing Cash Flow | $7.4M-36.9% | $11.7M+68.6% | $6.9M+5571.2% | $122Kn/m | -$2.9M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
ZJYL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Gross Margin | 29.2%-11.2pp | 40.4%+6.2pp | 34.2%+1.9pp | 32.3%+1.7pp | 30.6% |
| Operating Margin | 2.9%-12.5pp | 15.5%+1.0pp | 14.5%+3.4pp | 11.1%-1.6pp | 12.7% |
| Net Margin | 5.8%-9.9pp | 15.6%+1.1pp | 14.5%+0.4pp | 14.1%+1.4pp | 12.7% |
| Return on Equity | 4.0%-8.7pp | 12.8%+0.8pp | 12.0%-5.8pp | 17.8%-1.0pp | 18.8% |
| Return on Assets | 2.2%-5.8pp | 8.0%-0.7pp | 8.8%-4.2pp | 12.9% | N/A |
| Current Ratio | 1.86-0.6x | 2.50-1.0x | 3.49+0.2x | 3.31 | N/A |
| Liabilities-to-Equity | 0.80+0.2x | 0.60+0.2x | 0.370.0x | 0.37 | N/A |
| Asset Turnover | 0.39-0.1x | 0.51-0.1x | 0.60-0.3x | 0.92 | N/A |
| FCF Margin | -18.0%-12.3pp | -5.8%-20.8pp | 15.1%+7.1pp | 8.0%-19.9pp | 27.9% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| JIN MEDICAL INTERNATIONAL LTD. ZJYL | FY2025 | $20.7M | $1.2M | 5.8% | $173.1M | 46/100 |
| Pro-Dex Inc New PDEX | FY2026 | $77.5M | $13.7M | 17.6% | $188.0M | 72/100 |
| Utah Medical Products Inc UTMD | FY2025 | $38.5M | $11.3M | 29.3% | $216.1M | 78/100 |
| KORU Medical Systems, Inc. KRMD | FY2025 | $41.1M | -$2.6M | -6.4% | $138.1M | 67/100 |
| Anteris Technologies Global Corp. AVR | FY2025 | $1.9M | -$94.1M | N/A | $615.0M | 22/100 |
Where JIN MEDICAL INTERNATIONAL LTD. Ranks
Frequently Asked Questions
What is JIN MEDICAL INTERNATIONAL LTD.'s annual revenue?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported $20.7M in total revenue for fiscal year 2025. This represents a -12.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is JIN MEDICAL INTERNATIONAL LTD.'s revenue growing?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) revenue declined by 12.0% year-over-year, from $23.5M to $20.7M in fiscal year 2025.
Is JIN MEDICAL INTERNATIONAL LTD. profitable?
Yes, JIN MEDICAL INTERNATIONAL LTD. (ZJYL) reported a net income of $1.2M in fiscal year 2025, with a net profit margin of 5.8%.
What is JIN MEDICAL INTERNATIONAL LTD.'s EBITDA?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had EBITDA of $852K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is JIN MEDICAL INTERNATIONAL LTD.'s gross margin?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a gross margin of 29.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is JIN MEDICAL INTERNATIONAL LTD.'s operating margin?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had an operating margin of 2.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is JIN MEDICAL INTERNATIONAL LTD.'s net profit margin?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a net profit margin of 5.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is JIN MEDICAL INTERNATIONAL LTD.'s return on equity (ROE)?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has a return on equity of 4.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is JIN MEDICAL INTERNATIONAL LTD.'s free cash flow?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) recorded an outflow of $3.7M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is JIN MEDICAL INTERNATIONAL LTD.'s operating cash flow?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) generated $2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are JIN MEDICAL INTERNATIONAL LTD.'s total assets?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had $53.4M in total assets as of fiscal year 2025, including both current and long-term assets.
What are JIN MEDICAL INTERNATIONAL LTD.'s capital expenditures?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) invested $6.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does JIN MEDICAL INTERNATIONAL LTD. spend on research and development?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) invested $1.6M in research and development during fiscal year 2025.
What is JIN MEDICAL INTERNATIONAL LTD.'s current ratio?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a current ratio of 1.86 as of fiscal year 2025, which is generally considered healthy.
What is JIN MEDICAL INTERNATIONAL LTD.'s liabilities-to-equity ratio?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a liabilities-to-equity ratio of 0.80 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is JIN MEDICAL INTERNATIONAL LTD.'s return on assets (ROA)?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) had a return on assets of 2.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is JIN MEDICAL INTERNATIONAL LTD.'s P/E ratio?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) trades at 145x earnings, its market capitalization divided by $1.2M net income, FY2025. The market capitalization is $173.1M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is JIN MEDICAL INTERNATIONAL LTD.'s price-to-sales ratio?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) trades at 8.4x sales, its market capitalization divided by $20.7M revenue, FY2025. The market capitalization is $173.1M as of Oct 30, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is JIN MEDICAL INTERNATIONAL LTD.'s Altman Z-Score?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has an Altman Z-Score of 5.80, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is JIN MEDICAL INTERNATIONAL LTD.'s Piotroski F-Score?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are JIN MEDICAL INTERNATIONAL LTD.'s earnings high quality?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) has an earnings quality ratio of 2.44x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is JIN MEDICAL INTERNATIONAL LTD.?
JIN MEDICAL INTERNATIONAL LTD. (ZJYL) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.